Skip to main navigation
  • Technology
  • Company
  • Collaborate
  • Careers
  • Investors
    • News & Events
      • News Releases
      • Events
      • Presentations
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
      • Investment Calculator
      • Analyst Coverage
    • Corporate Governance
      • Documents & Charters
      • Management Team
      • Board of Directors
      • Committee Composition
    • Financial Information
      • SEC Filings
      • Annual Reports
      • Quarterly Results
    • IR Resources
      • FAQs
      • Email Alerts
      • Contact IR
  • Blog
  • Contact
Nautilus Biotechnology
  • Technology
  • Company
  • Collaborate
  • Careers
  • Investors
    • News & Events
    • Stock Information
    • Corporate Governance
    • Financial Information
    • IR Resources
  • Blog
  • Contact

News Releases

  • News & Events
    • News Releases
    • Events
    • Presentations
  • Stock Information
    • Stock Quote & Chart
    • Analyst Coverage
  • Corporate Governance
    • Documents & Charters
    • Leadership
    • Board of Directors
    • Committee Composition
  • Financial Information
    • SEC Filings
    • Quarterly and Annual Results
  • IR Resources
    • FAQs
    • Email Alerts
    • Contact IR
Nautilus Biotechnology to Participate in the Capital One Spatial Biology & Proteomics Summit
Sep 23, 2022
Nautilus Biotechnology Joins Human Proteome Organization (HUPO) Industrial Advisory Board
Sep 01, 2022
Nautilus Biotechnology to Participate in the Morgan Stanley Global Healthcare Conference
Aug 30, 2022
Nautilus Biotechnology Reports Second Quarter 2022 Financial Results
Aug 02, 2022
Nautilus Biotechnology Appoints Eric Spence as Vice President of Instrument Engineering and Ken Kuhn, Ph.D., as Vice President of Reagent and Platform Development
Aug 01, 2022
Nautilus Biotechnology to Announce Second Quarter 2022 Financial Results on August 2, 2022
Jul 13, 2022
Nautilus Biotechnology Reports First Quarter 2022 Financial Results
May 03, 2022
Nautilus Biotechnology Appoints Gwen Weld as Chief People Officer and Sheri Wilcox, Ph.D., as Vice President of Affinity Reagent Development
Apr 12, 2022
Nautilus Biotechnology to Announce First Quarter 2022 Financial Results on May 3, 2022
Apr 07, 2022
Nautilus Biotechnology to Present at EuPA and AACR Meetings
Apr 04, 2022

Pagination

  • Current page 1
  • Page 2
  • Next page next ›
  • Last page last »
Displaying 1 - 10 of 14

Sign-up for updates

Sign Up

Nautilus Biotechnology

 

 

Corporate Headquarters
2701 Eastlake Avenue East
Seattle, WA 98102

 

 

 

Research Headquarters
835 Industrial Road, Suite 200
San Carlos, CA 94070

Nautilus Biotechnology

 

linkedin      twitter

info@nautilus.bio
+1 (206) 333-2001

© 2022 Nautilus Biotechnology Inc.

Privacy Policy | Terms